Direct DNA testing for fragile X syndrome

Area of Science:

• Genetics and Molecular Biology
• Human Genetics
• Neurodevelopmental Disorders

Background:

• Fragile X syndrome is linked to amplified trinucleotide (cytosine guanine guanine) repeats in the FMR-1 gene.
• Understanding mutation status is crucial for at-risk individuals and families.
• Previous risk assessments relied on linkage analysis, which can be ambiguous.

Purpose of the Study:

• To investigate the prevalence and characteristics of FMR-1 gene mutations in a large cohort.
• To evaluate the utility of trinucleotide repeat analysis for diagnosing fragile X syndrome.
• To re-evaluate and clarify carrier status and genetic risk assessments.

Main Methods:

• Analysis of trinucleotide (cytosine guanine guanine) repeat expansions in the FMR-1 gene.
• Restriction fragment size analysis (delta) to quantify repeat amplification.
• Study included 396 patients and 35 normal controls, encompassing individuals with and without family history.

Main Results:

• Full mutation (≥500 bp increase) observed in all cytogenetically positive males and females.
• Premutation (100-500 bp increase) identified in normal obligate carrier females.
• Identified full mutations in 2.2% of mentally impaired patients without a family history and premutations in males and females with unknown family history.

Conclusions:

• Trinucleotide repeat analysis of the FMR-1 gene is effective for diagnosing fragile X syndrome.
• This method allows for unambiguous determination of carrier status and genetic risk.
• The findings aid in refining risk assessments for families affected by fragile X syndrome.